IP Library Granted Patent US 8,008,255
Granted Patent B2
US 8,008,255 · App. 10/559,595 · Granted Aug 30, 2011

Methods and compositions for enhanced transmucosal delivery of peptides and proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,255
App. No.
10/559,595
Granted
Aug 30, 2011
Kind
B2
Abstract

Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY 3-36 , and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.

Claims (8)

1. A pharmaceutical composition for transmucosal administration comprising about 0.5% (w/v) of exendin-4; about 0.5% (w/v) of poly-arginine having an average molecular weight of about 141 kDa; and about 0.56% monosodium glutamate monohydrate (w/v), at a pH of about 4.5 and wherein the exendin-4 has the same net charge as the poly-arginine at the pH of the composition.

2. The composition of claim 1 , wherein said poly-arginine is poly-L-arginine.

3. The composition of claim 1 , wherein said composition further comprises a tonicifying agent, a viscosity-increasing agent, a bioadhesive agent, a preservative, or any combination thereof.

4. The composition of claim 1 , further comprising about 0.72% sodium chloride (w/v).

5. A pharmaceutical composition for transmucosal administration comprising about 0.5% (w/v) of exendin-4; about 1.0% (w/v) of poly-arginine having an average molecular weight of about 141 kDa; and about 0.56% monosodium glutamate monohydrate (w/v), at a pH of about 4.5 and wherein the exendin-4 has the same net charge as the poly-arginine at the pH of the composition.

6. The composition of claim 5 , wherein said poly-arginine is poly-L-arginine.

7. The composition of claim 5 , wherein said composition further comprises a tonicifying agent, a viscosity-increasing agent, a bioadhesive agent, a preservative, or any combination thereof.

8. The composition of claim 5 , further comprising about 0.72% sodium chloride (w/v).

Assignments (5)
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP Recorded Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →
CHANGE OF NAME Recorded Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0340 →
RELEASE OF SECURITY INTEREST Recorded Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0342 →
SECURITY AGREEMENT Recorded Nov 8, 2011
From: AMYLIN PHARMACEUTICALS, INC.
To: ELI LILLY AND COMPANY
Reel/Frame 027192/0334 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FILING DATES FROM NULL TO 11/30/05 AND TRANMUCOSAL TO THE CORRECT SPELLING TRANSMUCOSAL PREVIOUSLY RECORDED ON REEL 017076 FRAME 0442. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT TO RE-RECORD ASSIGNMENT PREVIOUSLY RECORDED UNDER REEL AND FRAME 017076/0442. Recorded Jul 28, 2006
From: ONG, JOHN; JENNINGS, ROBERT; STETSKO, GREGG
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 018134/0159 →